• Mira Smart Conferencing
  • Home
  • Table of Contents
  • Advanced Search
 
Advanced Search

Browse All

Current Filters

CLEAR FILTER x

TITLE

Session Name:

  • S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches

Filter

Partial Search: Partial searches may be entered manually by pressing enter in the filter input field.
Author Filter: Selecting one or more Authors from the Author drop down list will filter results by Author last name(s) only.

Displaying 6 - 10 of 10

  • Page:
  • 1
  • 2

Effectiveness of Eculizumab Treatment by Time from Diagnosis in Patients with Generalized Myasthenia Gravis: A Retrospective Electronic Medical Record Analysis

Author:Muppidi, Srikanth   Lee, Justin   Habib, Ali   Howard, James   Klink, Andrew   Kielhorn, Adrian   Sabatella, Guido   Nowak, Richard   

Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S15.006  

Author Institution:Stanford Neuroscience Health Center, Stanford, CA  Alexion, AstraZeneca Rare Disease, Boston, MA  University of California, Irvine, Orange, CA  The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC  Cardinal Health, Philadelphia, PA  Yale University School of Medicine, New Haven, CT  

  • View Abstract
  • View Disclosure

Facilitated Subcutaneous Immunoglobulin 10% for CIDP: Interim Results from a Long-term Safety and Tolerability Study

Author:Hadden, Robert DM   Andersen, Henning   Bril, Vera   Basta, Ivana   Rejdak, Konrad   Djordjevic, Gordana   Greco, Erin   Hasan, Shabbir   French, James   Yel, Leman   Ay, Hakan   

Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S15.007  

Author Institution:Neurology Department, King’s College Hospital, London, United Kingdom  Aarhus University, Aarhus , Denmark  The Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, ON, Canada  University of Belgrade, Faculty of Medicine, Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia  Department of Neurology, Medical University of Lublin, Lublin, Poland  Neurology Clinic, University Clinical Center of Nis, Nis, Serbia  Takeda Development Center Americas, Inc., Cambridge, MA  

  • View Abstract
  • View Disclosure

Preliminary Efficacy and Safety Data from the Phase 2 Trial of Riliprubart (SAR445088), a Humanized Monoclonal Antibody Targeting Complement C1s, in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Author:Querol, Luis   Lewis, Richard   Hartung, Hans-Peter   Van Doorn, Pieter   Wallstroem, Erik   Luo, Xiaodong   Alonso Alonso, Miguel   Atassi, Nazem   Hughes, Richard   

Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S15.008  

Author Institution:Hospital de la Santa Creu i Sant Pau, Barcelona, Spain  Cedars Sinai Medical Center, Los Angeles, CA  Heinrich Heine University , Dusseldorf, Germany  Erasmus MC, University Medical Center, Rotterdam, Netherlands  Sanofi R&D, Neurology Development, Cambridge, MA  Sanofi R&D, Biostatistics and Programming, Bridgewater, NJ  UCL Queen Square Institute of Neurology, University College London, London, United Kingdom  

  • View Abstract
  • View Disclosure

Characterizing Monomelic Presentations of Demyelinating Neuropathy, or “Chronic Inflammatory Demyelinating Mononeuropathy” (CIDM)

Author:Swart, Grace   Shelly, Shahar   Lamb, Christopher   Pinto, Marcus Vinicius   Beecher, Grayson   Aragon Pinto, Catarina   Klein, Christopher   Engelstad, JaNean   Amrami, Kimberly   Spinner, Robert   Dyck, P. James B.   

Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S15.009  

Author Institution:Mayo Clinic, Rochester, MN  Rambam Medical Center, Haifa, Israel  Mayo Clinic, Jacksonville, FL  University of Alberta, Edmonton, AB, Canada  

  • View Abstract
  • View Disclosure

Long-term Efficacy and Safety of Ravulizumab, a Long-acting Terminal Complement Inhibitor, in Adults with Anti-acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis: Final Results from the Phase 3 CHAMPION MG Open-label Extension

Author:Vu, Tuan   Mantegazza, Renato   Annane, Djillali   Katsuno, Masahisa   Meisel, Andreas   Nicolle, Michael   Bril, Vera   Aguzzi, Rasha   Frick, Glen   Howard, James   

Session Name:S15: Autoimmune Neuromuscular Diseases: New Observations and Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S15.010  

Author Institution:University of South Florida Morsani College of Medicine, Tampa, FL  Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy  Hôpital Raymond Poincaré, Garches, France  Nagoya University Graduate School of Medicine, Nagoya, Japan  Charité Universitätsmedizin Berlin, Berlin, Germany  London Health Sciences Centre, London, ON, Canada  University of Toronto, Toronto, ON, Canada  Alexion, AstraZeneca Rare Disease, Boston, MA  The University of North Carolina, Chapel Hill, NC  

  • View Abstract
  • View Disclosure

Displaying 6 - 10 of 10

  • Page:
  • 1
  • 2

© 2015 Mira Smart Conference | http://www.mirasmart.com